

10.1 Introduction

Most vertebrates exhibit age-related decline in physiological function, particularly in locomotion. Loss of muscle volume and bone mass in late life is a hallmark of aging and resembles tissue obsolescence caused by disuse. However, some human populations lose bone mass more rapidly than would be predicted by normal aging. These individuals are diagnosed as having senile osteoporosis, one of the most prevalent geriatric disorders and one that seriously decreases quality of life in the elderly. As noted throughout this book, mice and rats are the most frequently used models to study osteoporosis, its treatment and prevention, and concomitant pathogenesis. Both mice and rats have an approximately 3-year lifespan. Bone mass peaks within the first quarter of life and then declines with age. This chapter describes age-related bone loss in laboratory rodents.

10.2 Aged Mice

Significant decreases in bone mass during the latter half of life are observed in laboratory rodents, such as mice and rats. Most studies of aged rodents focus on the anatomy and mechanism of age-related bone loss, a critical factor for senile osteoporosis, but the phenomenon can also be seen as part of the normal aging process. In most

studies of senescence, mice of 18–30 months of age are used as models of aging. However, genetic manipulation of mice to study aging may require 2 years before a particular phenotype emerges, making it difficult for a postdoc to complete the study or to attain grant support. Fortunately, although the sources and strains are still limited, aged mice can be obtained from some resources, such as the National Institute on Aging (NIA, USA), which provides aged rodents only for academic and nonprofit research institutes.

Among mouse strains, C57BL/6 is most often used to study age-related bone loss. Age-related changes in bone structure and skeletal mass seen in this strain are reportedly representative of those observed in human aging.^{1,4} One study showed that bone volume/tissue volume (BV/TV), trabecular number (Tb.N), and connectivity decrease with age, whereas cortical thickness increases between 6 weeks and 6 months of age and then declines.³ In the same study, cortical area (Ct.Ar) was not markedly changed between 6 and 24 months, and skeletal tissue weight of the tibia defatted by organic solvents was maximal at 12 months of age and then the fat-free weight decreased. The male mice used in this study showed no changes in serum testosterone level, suggesting that age-related bone loss in male C57BL/6 mice is apparently independent of androgen deficiency.³ Female mice do not appear to experience menopause but show age-related retardation of estrous cycles.⁵ Age-related bone loss in trabecular bones of vertebra and femora is more pronounced in female mice,² which show decreases in trabecular bone as early as 2–6 months of age. However, age-related changes in the parameters of bone formation and resorption differ among femoral mid-diaphysis, metaphysis, and lumbar vertebrae, which also differ in composition of trabecular and cortical bones and in mechanical properties.^{1,2,4} Serum markers of aged C57BL/6 mice suggest a high

K. Watanabe
Department of Bone and Joint Disease, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan
e-mail: kwatanab@ncgg.go.jp

turnover state of bone metabolism after 24 months of age.⁴ Assessment of mechanical properties by three-point flexure tests also reveals that the long bones are maturing between 3 and 10 months of age.¹ From time points representing peak bone mass, parameters such as bone mass, whole bone stiffness, and energy to fracture decrease by 24 months of age, whereas periosteal perimeter and cross-sectional moments of inertia continue to increase until 24 months. The growing phase when bone formation predominates ends and the lacuno-canalicular network of osteocytes is well aligned by 3 months of age, corresponding to the time of mechanical maturity.⁶

Among factors regulating osteoclastogenesis, receptor activator of NF- κ B ligand (RANKL) expression increases with age, but expression of osteoprotegerin (OPG), a decoy RANK inhibitor, slightly decreases. In mice, RANKL expression is inversely correlated with trabecular bone volume in terms of age-related changes.⁷ Such age-related expression patterns are reproduced in *ex vivo* culture of the bone marrow adherent cell fraction within 7 days but diminish in longer-term cultures (~28 days). Expression of M-CSF, another factor critical for osteoclastogenesis, also increases in the bone marrow of aged mice.⁸ When osteoclast differentiation is induced by only RANKL and M-CSF without stromal cells, a greater number of osteoclasts are generated from bone marrow of aged mice compared to younger mice, suggesting that the osteoclast precursor pool increases with age.⁸ Thus, both stromal and hematopoietic factors associated with osteoclastogenesis are elevated upon aging, suggesting a correlation with age-related bone loss.

Insulin-like growth factor (IGF) is a well-known factor governing cell survival and somatic tissue growth and maintenance. IGF acts as an anabolic agent for bones as well as muscles and cartilage.^{9,10} In aged C57BL/6 mice, growth stimulatory and survival activities of IGF significantly decrease.¹¹ Although expression of the IGF-1 receptor in aged mice is increased, receptor responsiveness, as evidenced by downstream MAPK and PI3K activation, is markedly reduced. Intermittent treatment with parathyroid hormone (PTH) is known to be a potential anabolic therapy among few other candidates.¹² Knopp et al. reported that 18-month-old C57BL/6 mice exhibit more pronounced increases in spinal bone mineral density (BMD) than do their 3-month-old counterparts in response to intermittent PTH injections, but those increases are not seen in the

femur.¹³ Mechanical stress plays critical roles in development and maintenance of the skeletal system, including bones. Low-magnitude cyclic loading, which stimulates bone formation in young mice, is not sufficient to initiate bone formation in 21-month-old mice.¹⁴ Thus, either responsiveness to various anabolic stimuli is impaired or the response threshold is shifted, or both occur in the aged skeleton.

10.3 Senescence-Accelerated Mice

The senescence-accelerated mouse (SAM), developed by Takeda's Lab at Kyoto University, originated from the AKR/J strain.¹⁵ SAM strains fall into two categories: P (senescence-prone) inbred strains, which exhibit an accelerated aging phenotype, and R (senescence-resistant) strains, which age normally. Several SAM strains are now commercially available. Among them, SAMP6 is often used as a mouse model of senile osteoporosis.¹⁶ SAMP6 mice show frequent fractures in their tibias and exhibit low peak bone mass, which underlies the accelerated age-related osteoporotic phenotype. Jilka et al. determined the cellular basis of the SAMP6 phenotype and found that the number of osteoblast progenitors in the bone marrow was not altered in this strain at prepuberty (1 month) but decreased significantly at adult ages (~4 months).¹⁷ Age-dependent decreases in BMD were also observed. A decline of histomorphometrical analysis parameters was pronounced not only in bone formation but also in resorption, resulting in reduced bone turnover. The number of osteoclasts in vertebra and femur was significantly reduced, and osteoclast formation in *ex vivo* bone marrow culture was markedly decreased. When bone marrow cells were cocultured with osteoblasts from wild-type mice, osteoclast formation from SAMP6 bone marrow cells was even higher than that seen in the control strain, suggesting that defects in osteoclast formation are caused by impairment in supporting roles of the osteoblast/stromal cell fraction. The authors of this study concluded that the decreased bone mass phenotype seen in SAMP6 mice was due to defects in osteoblastogenesis.¹⁷ Such defects in SAMP6 mice also promote resistance to bone loss following sex hormone deficiency induced by gonadectomy.¹⁸ Increased adipogenesis in the bone marrow of the SAMP6 strain has also been observed, and

[Attd]

expression of an anti-adipogenic cytokine, interleukin-11, was decreased in bone marrow stromal cells of this strain.^{19,20} Silva et al. reported that bone-forming activity of SAMP6 osteoblasts is normal, although the number of osteoblasts in the bone marrow was markedly reduced.²¹⁻²³ From 2 to 12 months of age, calcein-labeled surfaces in SAMP6 femur and tibia were significantly decreased in endocortical surfaces (inside the long bones) but not in periosteal surfaces (outside the bone), suggesting that SAMP6 mice possess a marrow defect.²³ Interestingly, bone marrow transplantation from normal to recipient SAMP6 mice resulted in a significant increase in trabecular bone and BMD.²⁴⁻²⁶ This finding confirms that the defect in SAMP6 mice originates in bone marrow and can be rescued by normal marrow.

The SAMP6 strain has been used to conduct a whole genome scan for quantitative trait loci (QTLs) to identify determinants of bone mass.²⁷⁻²⁹ Shimizu et al. analyzed QTLs of the F2 progeny obtained by crossing SAMP6 and SAMP2 mice, the latter of which possesses higher peak bone mass at 4 months of age.²⁹ In their study they determined cortical thickness of femurs and identified three *peak bone density (Pbd)* loci on chromosomes 11, 13, and X, corresponding to *Pbd1*, *Pbd2*, and *Pbd3*, respectively. They developed a congenic strain P6.P2-Pbd2, which possesses the genomic region from SAMP2 chromosome 13 that carries *Pbd2*, on a SAMP6 background. The congenic strain exhibited significantly higher peak bone mass than did SAMP6 mice.²⁸ Among the genes on the chromosome 13 locus, secreted frizzled-related protein 4 (*Sfrp4*) expression was significantly elevated in SAMP6 calvaria.²⁷ *Sfrp4* is an antagonist of Wnt ligands and thus inhibits Wnt- β -catenin signaling, which plays an important role in regulating bone mass. Recombinant SFRP4 protein suppressed osteoblast proliferation *in vitro*, suggesting that elevated *Sfrp4* expression underlies decreased bone formation seen in SAMP6 mice.²⁷

10.4 Rat Models of Aging

The aging rat also represents a good model to study age-related bone loss.³⁰⁻³⁵ Like C57BL/6 mice, the rat strain F344 has often been used for aging research, although Sprague-Dawley and Wistar rats have also

been analyzed. Trabecular bone volume of the vertebra of rats reportedly does not exhibit a decrease at 12 months of age, in contrast to mice^{31,32,34,35}; however, although the time course and structural changes in bone aging phenotypes differ between these rodents, both experience age-related bone loss. As a system, mice are advantageous because of the availability of genetic manipulation techniques, but because of their larger size rats represent a more appropriate system to study alterations in the vascular system. It has been suggested that blood vessel aging is associated with senility and the onset of geriatric diseases, and age-related alterations in the skeletal vasculature system also likely promote decreased blood flow in bone. Prosbly et al. determined age-related changes in femoral blood flow using rats of 4–6 and 24–26 months of age as models of young adult and aged animals, respectively.³⁶ Blood flow in aged rats was decreased to 70–80% of levels seen in young controls, and endothelial vasodilation of the principal nutrient artery was significantly reduced in aged animals relative to controls, whereas endothelium-independent vasodilation remained unchanged. The concentration of the intraluminal nitric oxide (NO), a vasodilator, was markedly decreased in the aged artery, suggesting that age-related reduction in NO signaling underlies decreased blood flow. The Louvain (LOU) rat exhibits an increased lifespan and is recognized as a model of healthy aging.³⁷ Duque et al. reported that aged LOU rats show low-turnover bone metabolism and an increase in bone marrow adiposity, which models the situation seen in human senile osteoporosis (Fig. 10.1).³⁸ Thus, rats are also useful to evaluate relationships between bone metabolism and physiological, age-related alterations.

10.5 Caloric Restriction

Caloric restriction (CR) is known to extend lifespan in flies, worms, and yeast as well as in mammals.^{39,40} CR reduces body mass, which is positively correlated with bone mass. As early as 1935, McCay et al. reported that dietary restriction of laboratory rats increased their lifespan.⁴¹ The authors also found that femoral bone density was decreased by CR, and hypothesized that this might be an indication of growth retardation. Currently, accumulated data indicate that CR delays




Fig. 10.1 μ CT analysis (a–f) to evaluate bone structure and sections of undecalcified bone stained with von Kossa (a–f, right panels) (magnification $\times 10$) to evaluate mineralized tissue (black) and fat volume (white). The figure shows 3D images of the trabecular bone and cross-sectional images of the cortical bone from rats aged 4, 20, and 30 months (a–f). The loss in bone volume, the reduction in both trabecular bone and cortical

thickness, and the increasing cortical porosity with age are visually apparent. Age-related changes in BMD (g) and BV/TV (h) showed a significant decline in both groups matching similar levels of bone mass and bone quality at 30 months of age (Note: a – $p < 0.01$, b – $p < 0.001$ compared with 4 months, one-way ANOVA and Dunnett’s test; c – $p < 0.01$, d – $p < 0.001$ males versus females) (From Duque et al.³⁸)

250 the progression and/or onset of age-related disorders, 251 such as neurodegeneration, renal failure, cataracts, 252 immune diseases, and cancer malignancy.^{42,43} Thus it is 253 plausible that CR could impact age-related bone loss.

254 Kalu et al. report that male F344 rats undergoing 255 lifelong CR show reduced age-related bone loss via 256 suppression of elevated serum PTH levels.⁴⁴ However, 257 Sanderson et al. observed that CR starting at around 258 17 months of age caused femoral bone loss in Lobund- 259 Wistar rats.⁴⁵ In another study, three mouse strains, 260 SENCAR, C57BL/6, and DBA/2, were subjected to a 261 6-month period of CR, begun at 10 weeks of age.⁴⁶ CR 262 increased vertebral BMD in SENCAR and C57BL/6 263 mice but decreased femoral BMD in SENCAR and 264 DBA/2 mice, indicating that the CR effect is dependent 265 on strain and experimental setting. Ten-week CR, 266 started at 14 weeks of age, reduced serum leptin and 267 IGF-1 levels, and reduced cortical bone thickness, 268 whereas vertebral BMD and trabecular bone volume in 269 mice were significantly increased.⁴⁷ Tatsumi et al. 270 reported that the effects of lifelong CR, started at 271 12 weeks of age, are biphasic on tibial bone metabolism 272 in C57BL/6 mice and F344 rats.⁴⁸ By 9 months

273 of CR, trabecular bone mass was decreased compared 274 to control ad libitum fed animals, and bone histomor- 275 phometric analyses revealed that the decrease was 276 mainly due to reduced bone formation. However, the 277 difference in bone mass between CR and controls was 278 not significant with longer periods of CR, and bone 279 mass was even higher in CR after 12 months of age, 280 suggesting that CR delays bone aging.⁴⁸ Although 281 overall these results differ, CR likely attenuates devel- 282 opmental acquisition of bone volume but delays age- 283 related bone loss.

284 Recently, it has been reported that administration of 285 rapamycin, an inhibitor of the TOR pathway that acts 286 as nutrient sensor in cells, extends lifespan in yeast, 287 worms, flies, and mice, mimicking CR.⁴⁹ The mam- 288 malian TOR (mTOR) pathway is known to regulate 289 FOXO signaling, which plays important roles in osteoblast 290 activity.^{50,51} The transcription factors FOXO and 291 ATF4 cooperatively regulate expression of osteocalcin, 292 which in an uncarboxylated form acts as a glucose- 293 regulating hormone.^{51,52} In addition, FOXO 294 mediates cellular defenses to oxidative stress, and 295 ATF4 regulates expression of *Rankl*.^{53,54} Thus, the

296 mTOR pathway may directly regulate bone metabo-
 297 lism. Future studies should address a potential effect of
 298 rapamycin on bone metabolism, especially on age-
 299 related bone loss in senile osteoporosis.

300 10.6 Age-Related Bone Loss

301 Osteopetrotic animals constitute another classic model
 302 of bone disease. Although osteopetrosis represents an
 303 opposite phenotype of osteoporosis, age-dependent
 304 decreases in bone mass have been reported in osteo-
 305 petrotic animals. In *op/op* mice, which lack functional
 306 M-CSF activity, alleviation of the osteopetrotic pheno-
 307 type has been observed with age.⁵⁵ As noted, both
 308 M-CSF and RANKL are essential regulators of osteo-
 309 clastogenesis, and their expression increases in the
 310 bone marrow of aged animals. The alleviation of
 311 osteopetrotic phenotypes seen in aging *op/op* mice
 312 suggests that an age-dependent factor(s), other than
 313 M-CSF and RANKL, plays a role in osteoclastogene-
 314 sis and may function in age-related acceleration of
 315 bone loss, whereas we cannot rule out the possibility
 316 that unknown age- or disease-specific factors may
 317 compensate for the impairment. Development of DNA
 318 microarray techniques has led to expression profiling
 319 of various tissues in circumstances including aging.
 320 Several studies indicate that upregulation of inflam-
 321 matory cytokine expression is a common feature of
 322 aged tissues and senescent cells.⁵⁶⁻⁵⁹ Several studies
 323 suggest that the activity of nuclear factor κ B (NF- κ B),
 324 a transcriptional regulator of cytokine expression,
 325 increases in tissues from animals with age-related dis-
 326 ease.⁶⁰⁻⁶² NF- κ B activity, as well as the presence of
 327 inflammatory cytokines, is a critical factor in osteo-
 328 clast formation.⁶³ Furthermore, tumor necrosis factor
 329 (TNF), a well-known inducer of NF- κ B activity, is a
 330 major adipokine expressed in fat tissues whose mass is
 331 significantly reduced in adult CR animals.^{64,65} TNF has
 332 also been proposed to be a cachexic hormone in vari-
 333 ous diseases.^{66,67} RANKL activity is significantly
 334 increased in the presence of TNF.^{68,69} Taken together,
 335 these observations suggest that age-related upregula-
 336 tion of the NF- κ B pathway may function in age-related
 337 bone loss, although the pathway has not yet been
 338 shown to play a causative role in aging. Thus, a hypo-
 339 theoretical aging factor, which stimulates NF- κ B pathway
 340 or sensitizes cells to NF- κ B signaling, may function

in age-related bone loss and senile osteoporosis. 341
 Age-dependent bone loss is also caused in part by loss 342
 of responsiveness to anabolic stimuli, and the hypo- 343
 theoretical aging factor(s) may be involved as well. The 344
 similar pathophysiology seen between human and ani- 345
 mal models suggests that aging factor(s) functioning 346
 in senile osteoporosis identified in rodent studies could 347
 be shared by humans. 348

References 349

- 350 1. Ferguson VL, Ayers RA, Bateman TA, Simske SJ. Bone 351
 development and age-related bone loss in male C57BL/6J 352
 mice. *Bone*. 2003;33(3):387-398. 353
- 354 2. Glatt V, Canalis E, Stadmeier L, Bouxsein ML. Age-related 355
 changes in trabecular architecture differ in female and male 356
 C57BL/6J mice. *J Bone Miner Res*. 2007;22(8):1197-1207. 357
- 358 3. Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL, 359
 Majumdar S. Changes in bone structure and mass with advanc- 360
 ing age in the male C57BL/6J mouse. *J Bone Miner Res*. 361
 2002;17(6):1044-1050. 362
- 363 4. Hamrick MW, Ding KH, Pennington C, et al. Age-related 364
 loss of muscle mass and bone strength in mice is associated 365
 with a decline in physical activity and serum leptin. *Bone*. 366
 2006;39(4):845-853. 367
- 368 5. Danilovich N, Sairam MR. Haploinsufficiency of the folli- 369
 cle-stimulating hormone receptor accelerates oocyte loss 370
 inducing early reproductive senescence and biological aging 371
 in mice. *Biol Reprod*. 2002;67(2):361-369. 372
- 373 6. Hirose S, Li M, Kojima T, et al. A histological assessment on the 374
 distribution of the osteocytic lacunar canalicular system using 375
 silver staining. *J Bone Miner Metab*. 2007;25(6):374-382. 376
- 377 7. Cao J, Venton L, Sakata T, Halloran BP. Expression of 378
 RANKL and OPG correlates with age-related bone loss in 379
 male C57BL/6 mice. *J Bone Miner Res*. 2003;18(2):270-277. 380
- 381 8. Cao JJ, Wronski TJ, Iwaniec U, et al. Aging increases 382
 stromal/osteoblastic cell-induced osteoclastogenesis and 383
 alters the osteoclast precursor pool in the mouse. *J Bone 384
 Miner Res*. 2005;20(9):1659-1668. 385
- 386 9. Giustina A, Mazziotti G, Canalis E. Growth hormone, insu- 387
 lin-like growth factors, and the skeleton. *Endocr Rev*. 2008; 388
 29(5):535-559. 389
- 390 10. Linkhart TA, Mohan S, Baylink DJ. Growth factors for bone 391
 growth and repair: IGF, TGF beta and BMP. *Bone*. 1996; 392
 19(1 Suppl):1S-12S. 393
- 394 11. Cao JJ, Kurimoto P, Boudignon B, Rosen C, Lima F, Halloran 395
 BP. Aging impairs IGF-I receptor activation and induces 396
 skeletal resistance to IGF-I. *J Bone Miner Res*. 2007;22(8): 397
 1271-1279. 398
- 399 12. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid 400
 hormone and teriparatide for the treatment of osteoporosis: 401
 a review of the evidence and suggested guidelines for its use. 402
Endocr Rev. 2005;26(5):688-703. 403
- 404 13. Knopp E, Troiano N, Bouxsein M, et al. The effect of aging 405
 on the skeletal response to intermittent treatment with para- 406
 thyroid hormone. *Endocrinology*. 2005;146(4):1983-1990. 407

- 395 14. Srinivasan S, Agans SC, King KA, Moy NY, Poliachik SL, 456
 396 Gross TS. Enabling bone formation in the aged skeleton via 457
 397 rest-inserted mechanical loading. *Bone*. 2003;33(6):946-955. 458
- 398 15. Takeda T, Hosokawa M, Takeshita S, et al. A new murine 459
 399 model of accelerated senescence. *Mech Ageing Dev*. 1981; 460
 400 17(2):183-194. 461
- 401 16. Matsushita M, Tsuboyama T, Kasai R, et al. Age-related 462
 402 changes in bone mass in the senescence-accelerated mouse 463
 403 (SAM). SAM-R/3 and SAM-P/6 as new murine models for 464
 404 senile osteoporosis. *Am J Pathol*. 1986;125(2):276-283. 465
- 405 17. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC. 466
 406 Linkage of decreased bone mass with impaired osteoblastogen- 467
 407 esis in a murine model of accelerated senescence. *J Clin Invest*. 468
 408 1996;97(7):1732-1740. 469
- 409 18. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. The 470
 410 effects of androgen deficiency on murine bone remodeling 471
 411 and bone mineral density are mediated via cells of the osteo- 472
 412 blastic lineage. *Endocrinology*. 1997;138(9):4013-4021. 473
- 413 19. Kodama Y, Takeuchi Y, Suzawa M, et al. Reduced expres- 474
 414 sion of interleukin-11 in bone marrow stromal cells of senes- 475
 415 cence-accelerated mice (SAMP6): relationship to osteopenia 476
 416 with enhanced adipogenesis. *J Bone Miner Res*. 1998; 477
 417 13(9):1370-1377. 478
- 418 20. Kajkenova O, Lecka-Czernik B, Gubrij I, et al. Increased 479
 419 adipogenesis and myelopoiesis in the bone marrow of 480
 420 SAMP6, a murine model of defective osteoblastogenesis 481
 421 and low turnover osteopenia. *J Bone Miner Res*. 1997; 482
 422 12(11):1772-1779. 483
- 423 21. Silva MJ, Brodt MD. Mechanical stimulation of bone forma- 484
 424 tion is normal in the SAMP6 mouse. *Calcif Tissue Int*. 485
 425 2008;82(6):489-497. 486
- 426 22. Silva MJ, Brodt MD, Etnner SL. Long bones from the senes- 487
 427 cence accelerated mouse SAMP6 have increased size but 488
 428 reduced whole-bone strength and resistance to fracture. 489
 429 *J Bone Miner Res*. 2002;17(9):1597-1603. 490
- 430 23. Silva MJ, Brodt MD, Ko M, Abu-Amer Y. Impaired marrow 491
 431 osteogenesis is associated with reduced endocortical bone 492
 432 formation but does not impair periosteal bone formation in 493
 433 long bones of SAMP6 mice. *J Bone Miner Res*. 2005; 494
 434 20(3):419-427. 495
- 435 24. Ichioka N, Inaba M, Kushida T, et al. Prevention of senile 496
 436 osteoporosis in SAMP6 mice by intrabone marrow injection 497
 437 of allogeneic bone marrow cells. *Stem Cells*. 2002;20(6): 498
 438 542-551. 499
- 439 25. Takada K, Inaba M, Ichioka N, et al. Treatment of senile 500
 440 osteoporosis in SAMP6 mice by intra-bone marrow injection 501
 441 of allogeneic bone marrow cells. *Stem Cells*. 2006; 502
 442 24(2):399-405. 503
- 443 26. Ueda Y, Inaba M, Takada K, et al. Induction of senile osteo- 504
 444 porosis in normal mice by intra-bone marrow-bone marrow 505
 445 transplantation from osteoporosis-prone mice. *Stem Cells*. 506
 446 2007;25(6):1356-1363. 507
- 447 27. Nakanishi R, Shimizu M, Mori M, et al. Secreted frizzled- 508
 448 related protein 4 is a negative regulator of peak BMD in 509
 449 SAMP6 mice. *J Bone Miner Res*. 2006;21(11):1713-1721. 510
- 450 28. Shimizu M, Higuchi K, Kasai S, et al. Chromosome 13 511
 451 locus, *Pbd2*, regulates bone density in mice. *J Bone Miner 512
 452 Res*. 2001;16(11):1972-1982. 513
- 453 29. Shimizu M, Higuchi K, Bennett B, et al. Identification of 514
 454 peak bone mass QTL in a spontaneously osteoporotic mouse 515
 455 strain. *Mamm Genome*. 1999;10(2):81-87. 516
30. Banu J, Wang L, Kalu DN. Age-related changes in bone 456
 mineral content and density in intact male F344 rats. *Bone*. 457
 2002;30(1):125-130. 458
31. Kiebzak GM, Smith R, Gundberg CC, Howe JC, Sacktor B. 459
 Bone status of senescent male rats: chemical, morphometric, 460
 and mechanical analysis. *J Bone Miner Res*. 1988;3(1): 461
 37-45. 462
32. Kiebzak GM, Smith R, Howe JC, Gundberg CM, Sacktor B. 463
 Bone status of senescent female rats: chemical, morphomet- 464
 ric, and biomechanical analyses. *J Bone Miner Res*. 1988; 465
 3(4):439-446. 466
33. Turner CH, Takano Y, Owan I. Aging changes mechanical 467
 loading thresholds for bone formation in rats. *J Bone Miner 468
 Res*. 1995;10(10):1544-1549. 469
34. Wang L, Banu J, McMahan CA, Kalu DN. Male rodent 470
 model of age-related bone loss in men. *Bone*. 2001;29(2): 471
 141-148. 472
35. Barbier A, Martel C, de Vernejoul MC, et al. The visualiza- 473
 tion and evaluation of bone architecture in the rat using 474
 three-dimensional X-ray microcomputed tomography. 475
J Bone Miner Metab. 1999;17(1):37-44. 476
36. Prisyby RD, Ramsey MW, Behnke BJ, et al. Aging reduces 477
 skeletal blood flow, endothelium-dependent vasodilation, 478
 and NO bioavailability in rats. *J Bone Miner Res*. 2007; 479
 22(8):1280-1288. 480
37. Alliot J, Boghossian S, Jourdan D, et al. The LOU/c/jall rat 481
 as an animal model of healthy aging? *J Gerontol A Biol Sci 482
 Med Sci*. 2002;57(8):B312-B320. 483
38. Duque G, Rivas D, Li W, et al. Age-related bone loss in the 484
 LOU/c rat model of healthy ageing. *Exp Gerontol*. 2009; 485
 44(3):183-189. 486
39. Mair W, Dillin A. Aging and survival: the genetics of life 487
 span extension by dietary restriction. *Annu Rev Biochem*. 488
 2008;77:727-754. 489
40. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, 490
 and aging. *Science*. 1996;273(5271):59-63. 491
41. McCay CM, Crowell MF, Maynard LA. The effect of 492
 retarded growth upon the length of life span and upon the 493
 ultimate body size. *J Nutr*. 1935;10:63-79. 494
42. Masoro EJ. Overview of caloric restriction and ageing. *Mech 495
 Ageing Dev*. 2005;126(9):913-922. 496
43. Weindruch R, Sohal RS. Seminars in medicine of the Beth 497
 Israel Deaconess Medical Center. Caloric intake and aging. 498
N Engl J Med. 1997;337(14):986-994. 499
44. Kalu DN, Hardin RH, Cockerham R, Yu BP. Aging and 500
 dietary modulation of rat skeleton and parathyroid hormone. 501
Endocrinology. 1984;115(4):1239-1247. 502
45. Sanderson JP, Binkley N, Roecker EB, et al. Influence of fat 503
 intake and caloric restriction on bone in aging male rats. 504
J Gerontol A Biol Sci Med Sci. 1997;52(1):B20-B25. 505
46. Brochmann EJ, Duarte ME, Zaidi HA, Murray SS. Effects 506
 of dietary restriction on total body, femoral, and vertebral 507
 bone in SENCAR, C57BL/6, and DBA/2 mice. *Metabolism*. 508
 2003;52(10):1265-1273. 509
47. Hamrick MW, Ding KH, Ponnala S, Ferrari SL, Isaacs CM. 510
 Caloric restriction decreases cortical bone mass but spares 511
 trabecular bone in the mouse skeleton: implications for the 512
 regulation of bone mass by body weight. *J Bone Miner Res*. 513
 2008;23(6):870-878. 514
48. Tatsumi S, Ito M, Asaba Y, Tsutsumi K, Ikeda K. Life-long 515
 caloric restriction reveals biphasic and dimorphic effects on 516

- 517 bone metabolism in rodents. *Endocrinology*. 2008;149(2):
518 634-641.
- 519 49. Katewa SD, Kapahi P. Dietary restriction and aging, 2009.
520 *Aging Cell*. 2010;9(2):105-112.
- 521 50. Ambrogini E, Almeida M, Martin-Millan M, et al. FoxO-
522 mediated defense against oxidative stress in osteoblasts is
523 indispensable for skeletal homeostasis in mice. *Cell Metab*.
524 2010;11(2):136-146.
- 525 51. Rached MT, Kode A, Xu L, et al. FoxO1 is a positive regula-
526 tor of bone formation by favoring protein synthesis and
527 resistance to oxidative stress in osteoblasts. *Cell Metab*.
528 2010;11(2):147-160.
- 529 52. Rached MT, Kode A, Silva BC, et al. FoxO1 expression in
530 osteoblasts regulates glucose homeostasis through regula-
531 tion of osteocalcin in mice. *J Clin Invest*. 2010;120(1):
532 357-368.
- 533 53. Eleftheriou F, Ahn JD, Takeda S, et al. Leptin regulation of
534 bone resorption by the sympathetic nervous system and
535 CART. *Nature*. 2005;434(7032):514-520.
- 536 54. Manolagas SC, Almeida M. Gone with the Wnts: beta-
537 catenin, T-cell factor, forkhead box O, and oxidative stress in
538 age-dependent diseases of bone, lipid, and glucose metabo-
539 lism. *Mol Endocrinol*. 2007;21(11):2605-2614.
- 540 55. Begg SK, Bertoncello I. The hematopoietic deficiencies in
541 osteopetrotic (op/op) mice are not permanent, but progres-
542 sively correct with age. *Exp Hematol*. 1993;21(4):493-495.
- 543 56. Blalock EM, Chen KC, Sharrow K, et al. Gene microarrays
544 in hippocampal aging: statistical profiling identifies novel
545 processes correlated with cognitive impairment. *J Neurosci*.
546 2003;23(9):3807-3819.
- 547 57. Lee CK, Klopp RG, Weindruch R, Prolla TA. Gene expres-
548 sion profile of aging and its retardation by caloric restriction.
549 *Science*. 1999;285(5432):1390-1393.
- 550 58. Melov S, Hubbard A. Microarrays as a tool to investigate the
551 biology of aging: a retrospective and a look to the future. *Sci*
552 *Aging Knowl Environ*. 2004;2004(42):re7.
- 553 59. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senes-
554 cence-associated secretory phenotype: the dark side of tumor
555 suppression. *Annu Rev Pathol*. 2010;5:99-118.
- 556 60. Gosselin K, Abbadie C. Involvement of Rel/NF-kappa B
557 transcription factors in senescence. *Exp Gerontol*. 2003;
558 38(11-12):1271-1283.
- 559 61. Pasparakis M. Regulation of tissue homeostasis by NF-kappaB
560 signalling: implications for inflammatory diseases. *Nat Rev*
561 *Immunol*. 2009;9(11):778-788.
- 562 62. Sarkar D, Fisher PB. Molecular mechanisms of aging-
563 associated inflammation. *Cancer Lett*. 2006;236(1):13-23.
- 564 63. Novack DV, Teitelbaum SL. The osteoclast: friend or foe?
565 *Annu Rev Pathol*. 2008;3:457-484.
- 566 64. Hwang CS, Loftus TM, Mandrup S, Lane MD. Adipocyte
567 differentiation and leptin expression. *Annu Rev Cell Dev*
568 *Biol*. 1997;13:231-259.
- 569 65. Moller DE, Kaufman KD. Metabolic syndrome: a clinical
570 and molecular perspective. *Annu Rev Med*. 2005;56:45-62.
- 571 66. Spiegelman BM, Hotamisligil GS. Through thick and thin:
572 wasting, obesity, and TNF alpha. *Cell*. 1993;73(4):625-627.
- 573 67. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic
574 cytokine and therapeutic target. *Annu Rev Med*. 1994;45:-
575 491-503.
- 576 68. Chambers TJ. Regulation of the differentiation and function
577 of osteoclasts. *J Pathol*. 2000;192(1):4-13.
- 578 69. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors,
579 RANKL/RANK, and immunology. *Immunol Rev*. 2005;
580 208:19-29.

